BILI vs NYT

The Advanced Deterministic Scorecard reveals significant concerns with a weak Piotroski F-Score of 2/9, indicating poor financial health, and the absence of an Altman Z-Score limits distress risk assessment. Despite this, BILI shows strong recent price momentum with a 1Y return of +103.3%, robust revenue surprise trends, and a bullish analyst recommendation, offset by stretched valuation metrics such as a P/E of 128.46 versus a sector average of 19.92. Profitability margins and ROE remain below peer averages, while improving earnings surprises and cash flow trends suggest potential operational turnaround. The stock trades at a large premium to both Graham Number ($5.47) and intrinsic value ($1.82), implying high growth expectations are already priced in.

The New York Times Company exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally low Debt/Equity ratio of 0.02. However, the stock is severely overvalued, trading at $79.03 despite a Graham Number of $24.36 and an Intrinsic Value of $32.50. This valuation gap is exacerbated by a high PEG ratio of 3.79 and a bearish technical trend (10/100). While earnings beats are consistent, the combination of insider selling by the CEO and CFO and a current price exceeding the analyst target price ($74.11) suggests a significant downside risk.